The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?

Crommelin D J, Broich K, Holloway C, Meesen B, Preiningerova J L, Prugnaud J-L, Silva-Lima B

Mult Scler. 2016 Aug; 22(2 Suppl):47-59. PMID: 27465615. Abstract